Presented favorable preclinical safety data for JADE101 and a translational analysis of APRIL mediated biomarker responses at ...

In vivo preclinical proof-of-concept data presented at AHA and ESGCT demonstrating >90% LDL-C reduction in non-human primates ...

In July 2025, the FDA approved Longeveron’s Investigational New Drug (IND) application for its stem cell therapy laromestrocel as a potential treatment for pediatric dilated cardiomyopathy (DCM). The ...

Investments in the 2025 federal budget represent a critical opportunity to ensure the North continues to grow, attract workers, and remain "the engine that powers Ontario's and Canada's future, accord ...